Clinical Application of PARP Inhibitors in Ovarian Cancer - prIME Oncology
Do You Think Like the Experts
Do You Think Like the Experts

Clinical Application of PARP Inhibitors in Ovarian Cancer

Do You Think Like the Experts?

Not a member of My prIME? Join now for instant access.

Engage in an interactive expert discussion to determine if you think like the experts! Clinical Application of PARP Inhibitors in Ovarian Cancer: Do You Think Like the Experts?  focuses on the optimization of the treatment sequence in recurrent ovarian cancer across the disease continuum and is certain to impact your daily clinical practice.

Interactive Presentation

Interactive Presentation

Downloadable Slides

Downloadable Slides



Release Date

Release Date

Dec 20, 2018

Expiration Date

Dec 20, 2019

  • Robert L. Coleman, MD, FACOG, FACSThe University of Texas
    MD Anderson Cancer Center
    Houston, Texas, United States
  • Ana Oaknin, MD, PhDVall d’Hebron Institute of Oncology
    Barcelona, Spain
  • Eric Pujade-Lauraine, MD, PhDCentre Hospitalier Universitaire Hôtel-Dieu
    Paris, France
  • BRCA testing
  • Second-line treatment and subsequent maintenance options
  • Adverse event profile of PARP inhibitors and patient monitoring
  • Treatment in later lines with PARP inhibitors

This educational activity is designed for medical oncologists, gynecologists, and other healthcare providers involved in the management of patients with ovarian cancer.

After successful completion of this educational activity, participants should be able to:

  • Identify whether and when a patient with ovarian cancer is an appropriate candidate for treatment with a PARP inhibitor
  • Describe recent findings from clinical trials investigating PARP inhibitors in pretreated ovarian cancer
  • Compare and contrast the tolerability profiles of available PARP inhibitors in ovarian cancer

This educational activity is supported by a grant from AstraZeneca.

Independent Medical Education (IME)

This IME activity is organized by prIME Oncology. This activity provides content that is evidence-based, balanced, and free of commercial bias, with a primary objective to improve competence and performance of learners in order to improve patient care.


This activity is provided by prIME Oncology.

Disclosure Information

Disclosure of Relevant Financial Relationships

prIME Oncology assesses relevant financial relationships with its instructors, planners, managers, and other individuals who are in a position to control the content of IME activities. Any potential conflicts of interest that are identified are thoroughly vetted by prIME Oncology for fairness, balance, and scientific objectivity of data, as well as patient care recommendations. prIME Oncology is committed to providing its learners with high-quality IME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial entity.

The faculty reported the following financial relationships or relationships to products or devices they or their spouses/life partners have with commercial interest related to the content of this activity:

Dr Coleman has disclosed that he has received consulting fees from AbbVie; Debiopharma; Genmab; ImmunoGen; Merrimack; Navigant Consulting; Perthera; Vaniam Group, LLC; and Verastem. He has been a speaker for Onc Live and Roche. He also has been on scientific/advisory boards for AstraZeneca; Bayer Healthcare, Inc.; Caris Life Sciences; Cerulean; Clovis Oncology; Gamamabs; Janssen; Novocure; Precision Oncology; Roche; and Tesaro. He has performed funded research for Array Bio Pharmaceuticals, AstraZeneca, Clovis Oncology, EMD Serano, Gradalis, Janssen, and Merck. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

Dr Oaknin has disclosed that she has board membership with OEIW and the European Society for Medical Oncology. She has consulting fees from AstraZeneca, Clovis, , PharmaMar, Roche, and Tesaro. She has received honoraria for promotional speaker’s bureaus from AstraZeneca, Clovis, Roche, and Tesaro. Furthermore, she has been speaking and teaching for AstraZeneca and Roche. She has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in her presentation.

Dr Pujade-Lauraine has disclosed that he has received honoraria or consulting fees from AstraZeneca, Clovis, Incyte, Pfizer, Roche, and Tesaro. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

The employees of prIME Oncology have disclosed:

  • Robert Coleman, MD, FRCP, FRCPE (medical director content reviewer/planner) – chair of Inbiomotion Scientific and Clinical Advisory Board; consulting fees for advising on clinical trial protocol development from Amgen, Astellas, and Boehringer Ingelheim; intellectual property rights as co-inventor and patent holder of biomarker under development by Inbiomotion; independent medical education lectures at symposia supported by Amgen, Eisai, and Genomic Health; and travel expenses from Amgen for presentation of clinical trial data at ASCO 2018 conference
  • Amy Furedy, RN, OCN (scientific content reviewer/planner) – no relevant financial relationships
  • Trudy Stoddert, ELS (editorial content reviewer) – no relevant financial relationships

Disclosure Regarding Unlabeled Use

This activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration or European Medicines Agency. Please refer to the official prescribing information for each product discussed for discussions of approved indications, contraindications, and warnings.


Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.